Psychiatry · Clinical trials
Postpartum Depression Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About postpartum depression — and why its trials are hard
Postpartum depression (PPD) is a major depressive episode with onset during pregnancy or within weeks to months after delivery, affecting roughly one in eight new mothers and carrying serious risks for maternal and infant well-being. For decades treatment relied on standard antidepressants and psychotherapy, but PPD now has two disease-specific FDA approvals, both neuroactive steroids that act as positive allosteric modulators of GABA-A receptors, reflecting a distinct hormonal-withdrawal pathophysiology. Brexanolone (Zulresso, 2019) is a 60-hour intravenous infusion requiring monitored inpatient administration, while zuranolone (Zurzuvae, 2023) is a 14-day oral course offering far greater convenience. Both act rapidly, with separation from placebo on the Hamilton Depression Rating Scale (HAM-D) within days. Their approvals validated allopregnanolone-based mechanisms and rapid-acting antidepressant strategies. Challenges remain around access, cost, REMS requirements for brexanolone, and the durability of benefit beyond the treatment window. Disease-specific late-stage failures are few; the main setbacks for this drug class occurred in the broader major depressive disorder program rather than in PPD itself.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Brexanolone (Zulresso) | 2019 | Adults with PPD; 60-hour continuous IV infusion under REMS with monitoring | Two Phase 3 randomized placebo-controlled trials (Meltzer-Brody et al. 2018, The Lancet) | HAM-D (HAMD-17) total score change from baseline at 60 hours | Significant HAM-D reduction vs placebo at 60 hours; least-squares mean difference roughly 2.5-5.5 points depending on trial/dose (unverified exact figures) |
| Zuranolone (Zurzuvae) | 2023 | Adults with PPD; once-daily oral 50 mg for 14 days | SKYLARK Phase 3 randomized placebo-controlled trial (and ROBIN) | HAMD-17 total score change from baseline at Day 15 | HAM-D reduction of 15.6 vs 11.6 points, a 4.0-point difference favoring zuranolone (p=0.0007); separation seen as early as Day 3 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in postpartum depression development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Zuranolone (in major depressive disorder, adjacent program) — MOUNTAIN Phase 3 study in MDD (not PPD); endpoint HAMD-17 change at Day 15 | Failed to meet its primary endpoint in MDD, contributing to the FDA declining the broader MDD indication while PPD was approved | High placebo response, dose selection (a lower dose was studied), and inconsistent effect durability in the general MDD population versus the PPD population |
Choosing the right endpoint
Primary endpoints that matter in postpartum depression trials
- HAM-D (HAMD-17) — 17-item Hamilton Depression Rating Scale; primary endpoint for both brexanolone (60h) and zuranolone (Day 15)
- HAM-D remission (score <=7) — Categorical remission endpoint used as a key secondary measure
- CGI-I / CGI-S — Global clinician impression of improvement and severity, standard secondary endpoints
- EPDS (Edinburgh Postnatal Depression Scale) — PPD-specific patient-reported screening/outcome measure used as supportive secondary
How iNGENū runs postpartum depression trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Postpartum Depression clinical trials — FAQs
What drugs are FDA-approved specifically for postpartum depression?
How fast do these treatments work?
Why is brexanolone administered in a hospital?
Related
Explore more
Ready to discuss your postpartum depression trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal